{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:16:57Z","timestamp":1770920217924,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03515-7","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:35:04Z","timestamp":1770190504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study"],"prefix":"10.1186","volume":"27","author":[{"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann Christian","family":"Virchow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Borsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Ledanois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Kwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andra-Ecaterina","family":"Boca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"3515_CR1","unstructured":"Global Initiative for Asthma. The Global Strategy for Asthma Management and Prevention. GINA-2025-Strategy-Report. https:\/\/ginasthma.org\/wp-content\/uploads\/2025\/05\/GINA-Strategy-Report_2025-WEB-WMS.pdf"},{"key":"3515_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/all.16382","volume":"80","author":"G Varricchi","year":"2025","unstructured":"Varricchi G, Poto R, Lommatzsch M, Brusselle G, Braido F, Virchow JC, et al. Biologics and airway remodeling in asthma: early, late, and potential preventive effects. Allergy. 2025;80:408\u201322.","journal-title":"Allergy"},{"key":"3515_CR3","doi-asserted-by":"publisher","first-page":"A49","DOI":"10.1016\/j.chest.2024.06.050","volume":"166","author":"J Wisnivesky","year":"2024","unstructured":"Wisnivesky J, Lee A, Ankam J, Zubair N, Floquet S, Khan A, et al. Longitudinal trajectory of lung function in patients with uncontrolled asthma. Chest. 2024;166:A49\u201350.","journal-title":"Chest"},{"key":"3515_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4168\/aair.2019.11.6.763","volume":"11","author":"WJ Song","year":"2019","unstructured":"Song WJ, Lee JH, Kang Y, Joung WJ, Chung KF. Future risks in patients with severe asthma. Allergy Asthma Immunol Res. 2019;11:763\u201378.","journal-title":"Allergy Asthma Immunol Res"},{"key":"3515_CR5","doi-asserted-by":"publisher","first-page":"e028150","DOI":"10.1136\/bmjopen-2018-028150","volume":"9","author":"ET Thomas","year":"2019","unstructured":"Thomas ET, Guppy M, Straus SE, Bell KJL, Glasziou P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. BMJ Open. 2019;9:e028150.","journal-title":"BMJ Open"},{"key":"3515_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/thorax-2023-220972","volume":"79","author":"Y Colak","year":"2024","unstructured":"Colak Y, Afzal S, Marott JL, Vestbo J, Nordestgaard BG, Lange P. Type-2 inflammation and lung function decline in chronic airway disease in the general population. Thorax. 2024;79:349\u201358.","journal-title":"Thorax"},{"key":"3515_CR7","doi-asserted-by":"publisher","first-page":"20820","DOI":"10.1016\/S2213-2600(24)00362-X","volume":"13","author":"M Castro","year":"2025","unstructured":"Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, Gonzalez-Barcala FJ, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:20820.","journal-title":"Lancet Respir Med"},{"key":"3515_CR8","unstructured":"European Medicines Agency, Xolair. 2005. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xolair. Accessed 23 Jul 2025."},{"key":"3515_CR9","unstructured":"European Medicines Agency, Nucala. 2015. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala#product-info. Accessed 23 Jul 2025."},{"key":"3515_CR10","unstructured":"European Medicines Agency, Cinqaero. 2016. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cinqaero. Accessed 23 Jul 2025."},{"key":"3515_CR11","unstructured":"European Medicines Agency, Fasenra. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fasenra. Accessed 23 Jul 2025."},{"key":"3515_CR12","unstructured":"European Medicines Agency, Dupixent. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent. Accessed 23 Jul 2025."},{"key":"3515_CR13","unstructured":"European Medicines Agency, Tezspire. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tezspire. Accessed 23 Jul 2025."},{"key":"3515_CR14","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327.","journal-title":"Lancet"},{"key":"3515_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","volume":"22","author":"PG Gibson","year":"2021","unstructured":"Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, et al. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021;22:171.","journal-title":"Respir Res"},{"key":"3515_CR16","doi-asserted-by":"publisher","first-page":"175346662312217","DOI":"10.1177\/17534666231221771","volume":"18","author":"J Liao","year":"2024","unstructured":"Liao J, Tang J, Jiang Y, Wang Y, Ding J, He Y. Effects of Omalizumab on lung function in patients with moderate-to-severe allergic asthma: A systematic review and meta-analysis. Ther Adv Respir Dis. 2024;18:17534666231221771.","journal-title":"Ther Adv Respir Dis"},{"key":"3515_CR17","doi-asserted-by":"publisher","first-page":"107535","DOI":"10.1016\/j.rmed.2024.107535","volume":"224","author":"A Papi","year":"2024","unstructured":"Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, et al. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma. Respir Med. 2024;224:107535.","journal-title":"Respir Med"},{"key":"3515_CR18","doi-asserted-by":"crossref","unstructured":"Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018;52(5):1801393.","DOI":"10.1183\/13993003.01393-2018"},{"key":"3515_CR19","doi-asserted-by":"publisher","first-page":"105991","DOI":"10.1016\/j.rmed.2020.105991","volume":"191","author":"ED Bateman","year":"2022","unstructured":"Bateman ED, Khan AH, Xu Y, Guyot P, Chao J, Kamat S, et al. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Respir Med. 2022;191:105991.","journal-title":"Respir Med"},{"key":"3515_CR20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","volume":"151","author":"AT Akenroye","year":"2023","unstructured":"Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC, et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023;151:1269\u201376.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 2","key":"3515_CR21","doi-asserted-by":"publisher","first-page":"AB95","DOI":"10.1016\/j.jaci.2023.11.316","volume":"153","author":"I Surjancev","year":"2024","unstructured":"Surjancev I, Viswanathan R, Denlinger L, Mathur S. Real-World comparison of dupilumab to Anti-IL5 biologics for severe persistent asthma. J Allergy Clin Immunol. 2024;153(Suppl 2):AB95.","journal-title":"J Allergy Clin Immunol"},{"key":"3515_CR22","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.jaci.2024.07.029","volume":"154","author":"E Bleecker","year":"2024","unstructured":"Bleecker E, Blaiss M, Jacob-Nara J, Huynh L, Duh MS, Guo T, et al. Comparative effectiveness of dupilumab and Omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study. J Allergy Clin Immunol. 2024;154:1500\u201310.","journal-title":"J Allergy Clin Immunol"},{"key":"3515_CR23","doi-asserted-by":"crossref","unstructured":"Bleecker E, Blaiss M, Jacob-Nara J, Huynh L, Guo T, Ye M et al. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab. Allergy and Asthma Proceedings. 2024,45:219\u201331.","DOI":"10.2500\/aap.2024.45.240018"},{"key":"3515_CR24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1513\/AnnalsATS.202306-566OC","volume":"21","author":"CM Kearney","year":"2024","unstructured":"Kearney CM, Sangani R, Shankar D, et al. Comparative effectiveness of Mepolizumab, benralizumab and dupilumab among patients with Difficult-to-Control asthma. Ann Am Thorac Soc. 2024;21:866\u201374.","journal-title":"Ann Am Thorac Soc"},{"key":"3515_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4168\/aair.2024.16.3.253","volume":"16","author":"SY Park","year":"2024","unstructured":"Park SY, Lee SK, Song WJ, Kim MH, Ban GY, Kim JH, et al. Real-World effectiveness of biologics in patients with severe asthma: analysis of the KoSAR. Allergy Asthma Immunol Res. 2024;16:253\u201366.","journal-title":"Allergy Asthma Immunol Res"},{"key":"3515_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12890-024-02964-4","volume":"24","author":"MZ Kayser","year":"2024","unstructured":"Kayser MZ, Suhling H, Fuge J, Hinze CA, Drick N, Kneidinger N, et al. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy. BMC Pulm Med. 2024;24:149.","journal-title":"BMC Pulm Med"},{"key":"3515_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/JAA.S357548","volume":"15","author":"T Numata","year":"2022","unstructured":"Numata T, Araya J, Miyagawa H, Okuda K, Takekoshi D, Hashimoto M, et al. Real-World effectiveness of dupilumab for patients with severe asthma: A retrospective study. J Asthma Allergy. 2022;15:395\u2013405.","journal-title":"J Asthma Allergy"},{"key":"3515_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s41669-020-00221-y","volume":"5","author":"MH Roberts","year":"2021","unstructured":"Roberts MH, Ferguson GT. Real-World evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon Open. 2021;5:3\u201311.","journal-title":"Pharmacoecon Open"},{"key":"3515_CR29","doi-asserted-by":"crossref","unstructured":"Canonica GW, Virchow JC, Bourdin A, Jacob-Nara J, Borsos K, Stanford RH et al. Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE. ERJ Open Res. 2025;11(4):01217\u20132024.","DOI":"10.1183\/23120541.01217-2024"},{"key":"3515_CR30","doi-asserted-by":"crossref","unstructured":"Valliant S, Zhang S, Harvey J, Mu G, Jakes R, Emeanuru K et al. Demographic Characteristics of Patients Who Utilize Biologics for Severe Asthma: A Real-World European Perspective. American Thoracic Society; 2023: A4754-A4754: American Thoracic Society International Conference Abstracts].","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A4754"},{"key":"3515_CR31","unstructured":"European Respiratory Society. The Global Lung Function Initiative. 2025. https:\/\/www.ersnet.org\/science-and-research\/ongoing-clinical-research-collaborations\/the-global-lung-function-initiative\/. Accessed 23 Jul 2025."},{"key":"3515_CR32","unstructured":"European Respiratory Society. Global Lung Function Initiative (GLI) calculator. 2025. https:\/\/gli-calculator.ersnet.org\/index.html. Accessed 23 Jul 2025."},{"key":"3515_CR33","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.2147\/JAA.S375134","volume":"15","author":"AH Khan","year":"2022","unstructured":"Khan AH, Gray C, Eckert L, Amand C, Maroni J, Wang Z, et al. Impact of baseline lung function on future exacerbations in patients with moderate-to-severe asthma. J Asthma Allergy. 2022;15:1639\u201344.","journal-title":"J Asthma Allergy"},{"key":"3515_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.anai.2011.12.001","volume":"108","author":"RS Zeiger","year":"2012","unstructured":"Zeiger RS, Yegin A, Simons FE, Haselkorn T, Rasouliyan L, Szefler SJ, et al. Evaluation of the National Heart, Lung, and blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol. 2012;108:81\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3515_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/JAA.S425101","volume":"17","author":"TW Guilbert","year":"2024","unstructured":"Guilbert TW, Murphy KR, Hamelmann E, Ross KR, Gupta A, Fiocchi A, et al. Impact of lung function on asthma exacerbation rates in children treated with dupilumab: the VOYAGE study. J Asthma Allergy. 2024;17:81\u20137.","journal-title":"J Asthma Allergy"},{"key":"3515_CR36","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in Moderate-to-Severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"3515_CR37","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in Glucocorticoid-Dependent severe asthma. N Engl J Med. 2018;378:2475\u201385.","journal-title":"N Engl J Med"},{"key":"3515_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.anai.2023.11.006","volume":"132","author":"M Blaiss","year":"2024","unstructured":"Blaiss M, Bleecker ER, Jacob-Nara J, Nair R, Duh MS, Wang Z, et al. Real-world effectiveness of dupilumab in patients with asthma: findings from the US ADVANTAGE study. Ann Allergy Asthma Immunol. 2024;132:463\u2013e8461.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3515_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/all.15456","volume":"78","author":"A Papi","year":"2023","unstructured":"Papi A, Corren J, Castro M, Domingo C, Rogers L, Chapman KR, et al. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma. Allergy. 2023;78:233\u201343.","journal-title":"Allergy"},{"key":"3515_CR40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.amj.2007.06.007","volume":"26","author":"EA Panacek","year":"2007","unstructured":"Panacek EA. Performing chart review studies. Air Med J. 2007;26:206\u201310.","journal-title":"Air Med J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03515-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03515-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03515-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:26:48Z","timestamp":1770917208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03515-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3515"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03515-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received exemption from the Pearl Institutional Review Board along with an authorisation waiver.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB received research grants from AstraZeneca-MedImmune, Boehringer Ingelheim, Cephalon\/Teva, GSK, Novartis, Sanofi and Regeneron Pharmaceuticals Inc. and is a consultant to Med-in-Cell, Actelion, Merck, Roche and Chiesi Pharmaceuticals and an investigator\/coinvestigator for AstraZeneca-MedImmune, Boehringer Ingelheim, GSK, Novartis, Sanofi, Regeneron Pharmaceuticals, Inc., Chiesi Pharmaceuticals, Actelion, Merck, Roche, Vertex and Galapagos. GWC received research grants and lecturer or advisory board fees from A. Menarini, Allergy Therapeutics, AstraZeneca, Chiesi Pharmaceuticals, Faes, Firma, Genentech, GSK, HAL Allergy, Innovacaremd, Novartis, OM Pharma, Red Maple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes Greer and Uriach Pharma. JCV received research grants from Deutsche Forschungsgesellschaft, Land Mecklenburg-Vorpommern, GSK and MSD; is an advisory committee member of Avontec, Boehringer Ingelheim, Cipla, Chiesi Pharmaceuticals, Essex\/Schering Plough, Genzyme, GSK, Janssen-Cilag, MEDA, MSD, Mundipharma, Novartis, Regeneron Pharmaceuticals, Inc., Revotar, Roche, Sanofi-Aventis, Sandoz-Hexal, TEVA, UCB\/Schwarz-Pharma and others; has conducted independent lectures for and received honoraria from AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer Ingelheim, Chiesi Pharmaceuticals, Cipla, German Remedies, Essex\/Schering-Plough, Genzyme, GSK, Janssen-Cilag, Leti, MEDA, Merck, MSD, Mundipharma, Noramed, Novartis, Nycomed\/Altana, Pfizer, Providens, Regeneron Pharmaceuticals, Inc., Revotar, Sandoz-Hexal, Sanofi-Aventis, Stallergenes Greer, TEVA, UCB\/Schwarz-Pharma, Zydus\/Cadila and others. KB and W-HC were employees of Sanofi at the time of this study execution. RHS is an employee of AESARA Inc. and a paid consultant to Sanofi. OL and AG are employees of Sanofi and may hold stocks and\/or stock options in the company. JK and WG are employees of Regeneron Pharmaceuticals Inc. and may hold stocks and\/or stock options in the company. LH and MSD are employees of Analysis Group, Inc., which received research funds from Sanofi. LH and MSD served as consultants to GSK PLC., within the past 36 months, for which Analysis Group, Inc. received research funding. AE-B was an employee of Analysis Group, Inc. at the time of conception, conduct and completion of the study as well as during the manuscript development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}